| Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday | Editors | 08/31/20 | Boston |
| Akcea Therapeutics Is Returning to Parent Ionis Pharma in $500M Buyout | Frank Vinluan | 08/31/20 | Boston |
| Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal | Frank Vinluan | 08/31/20 | San Francisco |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests | Frank Vinluan | 08/27/20 | Seattle |
| AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial | Sarah de Crescenzo | 08/27/20 | New York |
| National Xconomy Awards Digital Ceremony Complimentary Tickets Now Available | Editors | 08/27/20 | National |
| Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout | Sarah de Crescenzo | 08/26/20 | San Diego |
| FDA Rejects Tricida Chronic Kidney Disease Drug, More Data Needed | Frank Vinluan | 08/25/20 | San Francisco |
| FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines | Sarah de Crescenzo | 08/24/20 | National |
| Yumanity to Merge With Proteostasis to Advance Neuro Drug Pipeline | Frank Vinluan | 08/24/20 | Boston |
| Astellas Reports Third Patient Death in Audentes Gene Therapy Study | Frank Vinluan | 08/21/20 | San Francisco |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts | Sarah de Crescenzo | 08/20/20 | National |
| Alzheon Lands $47M to Take Another Shot at a Pivotal Alzheimer’s Test | Frank Vinluan | 08/20/20 | Boston |
| FDA Rejects BioMarin Hemophilia Gene Therapy, Asks for More Data | Sarah de Crescenzo | 08/19/20 | National |
| J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout | Frank Vinluan | 08/19/20 | New York |
| Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold | Sarah de Crescenzo | 08/18/20 | San Diego |
| Unity Biotech Arthritis Drug Flunks Phase 2, Spelling Program’s End | Frank Vinluan | 08/18/20 | San Francisco |
| Genentech Gets FDA OK for Injectable Rare Neuroimmune Disease Drug | Sarah de Crescenzo | 08/18/20 | San Francisco |
| Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor | Sarah de Crescenzo | 08/17/20 | Boston |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Sanofi Reaches $3.68B Deal to Buy Principia and Partnered MS Drug | Frank Vinluan | 08/17/20 | Europe |
| Advisory Body Backs MesoBlast Therapy for Transplant Complication | Sarah de Crescenzo | 08/14/20 | New York |
| CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears | Frank Vinluan | 08/14/20 | Europe |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
